+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 100Years
All Genders
ID05764538

Open Trial of DAOIB to Treat Cognitive Impairment Caused by COVID-19

Led by Chang Gung Memorial Hospital · Updated on 2026-10-23

40

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of DAOIB in adults with cognitive impairments caused by long COVID. This open-label Phase 2 trial aims to study whether DAOIB can improve cognitive function, mood symptoms, overall functioning, and quality of life in these patients. The trial is sponsored by Chang Gung Memorial Hospital and targets individuals aged 18 to 100 years who meet specific health criteria. Participants will receive DAOIB for 24 weeks, with dosage adjustments every 8 weeks based on clinical evaluations. The study includes regular assessments at weeks 0, 8, 16, and 24 to monitor changes and effects. All patients receive the same treatment during the trial without a placebo group. During the study, participants undergo evaluations including the Alzheimers disease assessment scale for cognition, clinician interviews, activities of daily living scales, quality of life questionnaires, and mood and stress rating scales. These assessments occur at multiple time points to track progress. Safety and adherence are monitored throughout the 24-week period, with the main goal of measuring cognitive improvements and related outcomes.

CONDITIONS

Brief Title

DAOIB for the Treatment of Brain Fog

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here